Regulatory 2025-11-05 | Quarterly Report Q3 2025: Orviglance NDA Submitted to the FDA PDF Report Presentation Webcast
Regulatory 2025-08-21 | Half-Year Report 2025: Orviglance NDA Submission Approaching PDF Report Presentation Webcast
Regulatory 2025-05-16 | Quarterly Report Q1 2025: Positive Outcome of Orviglance FDA Meeting in Advance of the NDA Submission PDF Report Presentation Webcast
Regulatory 2025-04-11 | Annual Report 2024: Orviglance Advances to Registration Phase after Successful Phase 3 Study Completion PDF ESEF Report Presentation Webcast
Regulatory 2025-02-07 | Q4 and Full Year Report 2024: Completion of Full Study Report Reinforces Successful Outcomes of SPARKLE Phase 3 Study PDF Report Presentation Webcast
Regulatory 2024-11-07 | Quarterly Report Q3: Successful Outcome from Rights Issue with SEK 105 Million Extends Runway Until Late 2025 PDF Report Presentation Webcast
Regulatory 2024-08-15 | Half-Year Report 2024: Orviglance Completes Clinical Development with Successful Phase 3 Study PDF Report Presentation Webcast
Regulatory 2024-05-16 | Quarterly Report Q1: Primary Endpoint Met with Strong Headline Results in Orviglance Phase 3 Study PDF Report Presentation Webcast
Regulatory 2024-04-08 | Annual Report 2023: Solid Progress with Orviglance Phase 3 Patient Recruitment Completed and Headline Results Expected by May 2024 PDF Report Presentation Webcast
Regulatory 2024-02-09 | Q4 and Full Year Report 2023: Strengthened Financial Position Ahead of SPARKLE Phase 3 Study Headline Results in May PDF Report Presentation Webcast
Regulatory 2023-11-08 | QUARTERLY REPORT Q3 2023: Re-evaluation of SPARKLE Phase 3 Study Images Progresses According to Plan PDF Report Presentation Webcast
Regulatory 2023-08-18 | Half-Year report 2023: Re-evaluation required after intra-reader inconsistency in scoring of images from phase 3 study SPARKLE PDF Report Presentation Webcast
Regulatory 2023-05-11 | QUARTERLY REPORT Q1 2023: Orviglance phase 3 study, SPARKLE, Last Patient Last Visit (LPLV) has been completed PDF Report Presentation Webcast
Regulatory 2023-04-13 | Correction: Ascelia Pharma publishes annual report for 2022 PDF Report Presentation Webcast
Regulatory 2023-04-13 | Ascelia Pharma publishes annual report for 2022 PDF Report Presentation Webcast
Regulatory 2023-02-10 | QUARTERLY REPORT Q4 2022: Orviglance phase 3 study, SPARKLE, expected to be completed in Q1 2023. PDF Report Presentation Webcast
Regulatory 2022-11-04 | QUARTERLY REPORT Q3 2022: Successful completion of two out of three studies for regulatory submission PDF Report Presentation Webcast
Regulatory 2022-08-18 | Half-year report 2022: Strong results from Orviglance Food Effect Study PDF Report Presentation Webcast
